Synthaverse S.A. (WSE:SVE)

Poland flag Poland · Delayed Price · Currency is PLN
4.610
-0.040 (-0.86%)
Apr 2, 2025, 5:00 PM CET
17.90%
Market Cap 323.95M
Revenue (ttm) 62.66M
Net Income (ttm) 4.45M
Shares Out 70.27M
EPS (ttm) 0.06
PE Ratio 73.02
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 49,367
Average Volume 67,594
Open 4.660
Previous Close 4.650
Day's Range 4.600 - 4.670
52-Week Range 3.950 - 5.930
Beta 1.27
RSI 42.84
Earnings Date Apr 11, 2025

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1944
Employees 239
Stock Exchange Warsaw Stock Exchange
Ticker Symbol SVE
Full Company Profile

Financial Performance

In 2023, Synthaverse's revenue was 58.61 million, an increase of 16.32% compared to the previous year's 50.38 million. Earnings were 4.76 million, a decrease of -21.76%.

Financial Statements

News

There is no news available yet.